Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Liquidia Corporation Common Stock (LQDA) Price & Performance

Kymera Therapeutics Inc. Common StockTrade

Liquidia Corporation Common StockTrade

Price performance (Past 24H)

Key statistics

Kymera Therapeutics Inc. Common Stock vs Liquidia Corporation Common Stock — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Liquidia Corporation Common Stock trades at $33.66 (market cap $2.40B). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 3.7× Liquidia Corporation Common Stock's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, Liquidia Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Liquidia Corporation Common Stock for 0 Days on average.

	KYMR	LQDA
Market Cap	$8.87B	$2.40B
Volume	779,107	2,857,547
Sector	Health	Health
52-Week High	$127.31	$91.03
52-Week Low	$55.80	$22.02
Typical Hold Time	0 Days	0 Days
Enterprise Value	$8.26B	$2.30B

View details →View details →

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

KYMR

100% Buy0% Sell

Avg holding period · 0 Days

LQDA

62% Buy38% Sell

Avg holding period · 0 Days

Top news

Latest headlines on both assets

KYMR

View details →

LQDA

Bending Spoons jumps 41% as Berkshire Hathaway boosts stake; Antelope Enterprise and others also surge.Andrew Wynn · 8 hours agoBullish Liquidia shares jump 25% after settling patent lawsuits with United TherapeuticsProactive Investors · 16 hours agoBullish Liquidia settles patent dispute with United Therapeutics, stock jumps 42% despite $380M payout.24/7 Wall Street · 18 hours agoBullish View details →

About Kymera Therapeutics Inc. Common Stock

Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.

About Liquidia Corporation Common Stock

Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.